Roche to present data across broad and impactful neuroscience portfolio at 2022 AAN Annual Meeting

maximally sustaining IL-6 suppression in a chronic disease like NMOSD and enabling subcutaneous dosing every four weeks. Positive Phase III results for ENSPRYNG, as both monotherapy and in... | March 25, 2022

Related Keywords

Japan ,Kenya ,United States ,Canada ,South Korea ,Russia ,Switzerland ,America ,American ,Nathalie Meetz ,Levi Garraway ,Loren Kalm ,Impact Of Administration Ocrelizumab ,Sclerosis Care Center ,Genentech ,Drug Administration ,Head Of Global Product Development ,Risdiplam Clinical Trial Development Program ,European Union ,Roche Group ,American Academy Of Neurology ,European Medicines Agency ,Roche Group Media Relations ,American Academy ,Annual Meeting ,Chief Medical Officer ,Global Product ,Suboptimal Response ,Prior Disease Modifying Therapies ,Year Data ,Year Interim Results ,Term Suppression ,Regional Volume Loss ,Label Extension ,Confirmed Disability Progressions Analyses ,Open Label Extensions ,Disease Progression ,Post Hoc Analyses ,Baseline Disease Characteristics ,Hispanic Patients ,Multiple Sclerosis Enrolled ,Patterns Among Newly Diagnosed Patients ,Multiple Sclerosis ,Secondary Progressive Multiple Sclerosis ,Assess Efficacy ,Cognition Outcomes ,Cellular Responses ,Disease Modifying Therapies ,Prospective Study ,Home Infusion ,Patient Reported Outcomes ,Outcome Measures ,Open Label Rollover Study ,Subcutaneous Gantenerumab Long Term Safety ,Clinical Trials ,Early Alzheimer ,Aging And Dementia ,Clinical Aspects ,Cognitive Impairments ,Concept Study ,Preliminary Clinical Validity ,Remote Smartphone Based Self Assessments ,Remote Assessments ,Spinal Muscular ,On Site Child ,Preliminary Efficacy ,Safety Data ,Risdiplam Treated Infants ,Child Neurology ,Exploratory Efficacy Data ,Spinal Muscular Atrophy ,Receiving Treatment ,Risdiplam Treatment ,Pediatric Patients ,Neuromyelitis Optica Spectrum ,Term Safety ,Neuromyelitis Optica Spectrum Disorder ,Open Label Extension Periods ,Autoimmune Neurology ,Term Efficacy ,Results From The Open Label Extension Periods ,Open Label Study ,Satralizumab Investigating Novel Imaging ,Clinical Outcomes ,Duchenne Muscular Dystrophy ,Year Safety ,Functional Outcomes ,Trial Evaluating ,Treating Patients ,Orphan Drug Designation ,Breakthrough Therapy Designation ,Dow Jones Sustainability Indices ,Chugai Pharmaceutical ,Roche Holding Ag Stock Exchange ,News ,Information ,Press Release ,Maximally ,Sustaining ,Suppression ,N ,Hronic ,Disease ,Bike ,Nmosd ,End ,Nabling ,Subcutaneous ,Closing ,Very ,Four ,Positive ,Hase ,Wii ,Results ,Or ,Us ,Moth ,Monotherapy ,Nd Rog Ch0012032048 ,